Defatting strategies in the current era of liver steatosis
Related Experiment Video
Updated: Nov 4, 2025

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
Laura Ioana Mazilescu1,2,3, Markus Selzner1, Nazia Selzner1
1Ajmera Transplant Program, Toronto General Hospital, Ontario, Canada.
Abstract:
Liver steatosis is emerging as a major cause of chronic liver disease worldwide, mainly due to the increasing rate of obesity, type 2 diabetes, and metabolic syndrome. Because of the increased incidence of liver steatosis, many organs are currently declined for transplantation despite high demand and waiting list mortality. Defatting strategies have recently emerged as a means of rapidly reducing liver steatosis to expand the pool of available organs. This review summarises advances in defatting strategies in experimental and human models of liver steatosis over the last 20 years.
Related Concept Videos
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Lipid-Lowering Drugs: Statins and Miscellaneous Agents

